Coronary Artery Bypass Graft Degenerative Disease
1Minnesota Heart Institute Foundation, 920 East 28th Street, Suite 300, Minneapolis, MN 55407, USA.
Insights
Arterial grafts offer superior long-term patency in coronary artery bypass grafting (CABG) compared to vein grafts. Lifestyle modifications and aspirin are crucial for graft success and managing myocardial ischemia.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
- Vascular Biology
Background:
- Long-term patency of coronary artery bypass grafts (CABGs) is significantly influenced by conduit choice.
- Arterial grafts demonstrate superior patency rates compared to saphenous vein bypass grafts (SVGs).
- Management of myocardial ischemia requires optimizing graft function and addressing risk factors.
Purpose of the Study:
- To review critical factors influencing long-term patency of coronary artery bypass grafts.
- To outline optimal medical and interventional strategies for managing patients with coronary artery bypass grafts.
- To discuss treatment options for symptomatic patients with obstructed bypass grafts.
Main Methods:
- Review of current literature on coronary artery bypass graft patency and management.
- Analysis of the role of different graft conduits (arterial vs. venous).
- Evaluation of medical therapies including antiplatelets, statins, and lifestyle modifications.
- Assessment of interventional procedures like percutaneous transluminal coronary angioplasty (PTCA) and repeat CABG for graft-related ischemia.
Main Results:
- Arterial grafts are superior to SVGs for long-term CABG patency.
- Early and indefinite aspirin therapy is recommended; other antiplatelet agents offer limited added benefit.
- Aggressive reduction of low-density lipoprotein cholesterol (LDL-C) below 100 mg/dL, often with HMG CoA reductase inhibitors, is essential.
- Smoking cessation, blood pressure control, ideal body weight, and exercise are beneficial.
- Symptomatic patients with graft obstruction require interventions to restore myocardial perfusion.
- Successful PTCA and stenting of grafts can improve perfusion, but repeat CABG may be necessary.
- PTCA of native coronaries is an alternative in some cases.
- Restenosis rates after PTCA and risks of repeat CABG must be considered.
Conclusions:
- Conduit selection is paramount for CABG long-term success, favoring arterial grafts.
- Comprehensive medical management, including aspirin and statins, alongside lifestyle changes, is vital.
- Interventional strategies, including PTCA and repeat surgery, are effective for managing graft-related ischemia but require careful risk-benefit assessment.
Abstract:
The choice of conduit is the most important factor influencing long-term patency of coronary artery bypass grafts (CABGs); arterial grafts are far superior to saphenous vein bypass grafts (SVGs) in this regard. Aspirin therapy should be started early in the perioperative period and continued indefinitely. Warfarin (Coumadin; Dupont, Wilmington, DE) and other platelet inhibitors offer no added value to aspirin, but may be used with benefit in aspirin-intolerant patients. Every effort should be made to reduce low-density lipoprotein cholesterol (LDL-C) to a value well below 100 mg/dL. In most instances, this will require the use of an 3-hydroxy-3-methyglutaryl coenzyme A (HMG CoA) reductase inhibitor. Avoidance of cigarette smoking is imperative. Achieving a normal blood pressure, ideal body weight, and a regular exercise program are helpful. Those patients who have important obstruction in a SVG or arterial graft and who are symptomatic, or who have important myocardial ischemia with orjwithout symptoms should be treated with a procedure to improve perfusion to the myocardium supplied by the occluded bypass graft. Successful percutaneous transluminal coronary angioplasty (PTCA) and stenting of the obstructed graft usually will lead to improved myocardial perfusion, although in other clinical circumstances repeat CABG surgery will be required. On occasion, reperfusion of the myocardium can be achieved by PTCA of the native coronary artery with or without stenting while the degenerated graft is abandoned. When planning therapy for myocardial ischemia, the higher rate of PTCA related restenosis and the increased risks from repeat CABG must be carefully considered.
More Related Videos
09:12Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease III: Clinical Manifestations
01:27Coronary Artery Disease V: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy